Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

There are only limited treatment options for metastatic NRAS mutant melanoma patients with resistance to immune checkpoint inhibitors. Besides activation of the mitogen-activated protein (MAP) kinase pathway, they often have additional disturbances in cell cycle regulation. However, unlike BRAF muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Forschner, Andrea, Sinnberg, Tobias, Mroz, Gabi, Schroeder, Christopher, Reinert, Christian Philipp, Gatidis, Sergios, Bitzer, Michael, Eigentler, Thomas, Garbe, Claus, Niessner, Heike, Röcken, Martin, Roggia, Cristiana, Armeanu-Ebinger, Sorin, Riess, Olaf, Mattern, Sven, Nann, Dominik, Bonzheim, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959243/
https://www.ncbi.nlm.nih.gov/pubmed/33732653
http://dx.doi.org/10.3389/fonc.2021.643156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959243/
https://www.ncbi.nlm.nih.gov/pubmed/33732653
http://dx.doi.org/10.3389/fonc.2021.643156

Ejemplares similares